An interventional study of RD-X19 and RD-X19 Sham in COVID-19 Respiratory Infection and Influenza, sponsored by David Moss. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by David Moss · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.
Among the 966 studies in Influenza, Human with a site in United States, this one is the 527th largest by planned enrollment of the 843 interventional ones that give a count, is one of 27 that started in 2026, is one of 160 with no phase, reaches primary completion later than 68 of the 83 other live ones, and was the 951st registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 18–64 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
966 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 244 · Phase 3 127 · Phase 4 147
First in 1997; this study’s year is marked. 27 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 843 interventional studies, 261 across the 122 observational. Of the 841 that completed or were terminated, 434 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
435 of 966 have an industry lead sponsor. The 10 most frequent:
David Moss is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
David Moss has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
41 of the studies in Influenza, Human with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 41 to your calendar (.ics) → With an account.
Among the 966 studies in Influenza, Human with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.
Methods: Subjects 18 years and older working at a DoD medical facility and VA medical facility will be randomized into Active Treatment (Emit Bio ) and sham (inactive device). Basic demographic information will be obtained. Subjects will use the device at home every other day for 5 minutes. Baseline viral upper respiratory PCR panel will be obtained to ensure pre-existing infections are not counted. At first sign of upper respiratory infection symptoms, subjects will contact research personnel and have viral respiratory PCR panel obtained. Research coordinators will also contact subjects every two weeks to ask if they are experiencing or have experienced any upper respiratory symptoms or if they have experienced any side effects of treatment. Subjects reporting any current symptoms or symptoms in the prior 2 weeks will have upper respiratory PCR panel obtained. Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess secondary outcomes including duration of symptoms, missed days of work, outpatient medical visits, ED visits, hospitalizations, medication prescriptions for respiratory illness and over the counter treatments.
Screening visit (Approx 30 min):
Randomization:
Subjects will be randomized using block randomization (blocks of 6) into one of two research treatment groups, with approximately 50 subjects in each arm for a total of 100 subjects. The study staff assigning subjects to their group will be unblinded to the groups, but patients, investigators, and study staff conducting screening and gathering data will be blinded. The unique study code will be assigned in sequential order beginning with 001.
Group 1: Active RD-X19 every other day for 3 months Group 2: Sham RD-X19 every other day for 3 months
Visit 1 (week 0) (may be same day as screening visit) (approx. 30 minutes):
Visits 2-7 (weeks 2-12) (approx. 30 min) can be performed virtually or in person
Visit 7
-During the subjects final visit, they will be given a questionnaire regarding usage of the device
Device will only be used for a single patient and should be returned to research staff at the end of the study for disposal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: RD-X19
Device: RD-X19 Sham
* Subject will be given the RD-X19 device and shown how to use the device * Subjects will be instructed to use the device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout
* Subject will be given the sham RD-X19 device and shown how to use the device * Subjects will be instructed to use the sham device for 5 minutes every other day * Subject will be given "Instructions for Treatment" handout
difference in PCR confirmed URI (any virus)
difference in PCR confirmed URI (any virus) between active and sham groups between treatment period
Time frame: visit 2 (week 2), visit 3 (week 4), visit 4 (week 6), visit 5 (week 8), visit 6 (week 10), visit 7 (week 12)
duration of symptoms
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess duration of symptoms (days)
Time frame: upper respiratory infection duration, an average of 2 weeks
missed days of work
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess missed days of work
Time frame: upper respiratory infection duration, an average of 2 weeks
outpatient visits
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of outpatient visits
Time frame: upper respiratory infection duration, an average of 2 weeks
emergency department visits
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of emergency department visits
Time frame: upper respiratory infection duration, an average of 2 weeks
hospitalizations
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number of hospitalizations
Time frame: upper respiratory infection duration, an average of 2 weeks
Wisconsin Upper Respiratory Symptom Survey (WURSS 24)
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess daily symptom severity score using WURSS 24. The WURSS 24 is an illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infections. Subjects rate their symptoms and daily impairments using 0-7-point Likert scales. Minimum value is 0, maximum value is 154. Higher score means worse outcome.
Time frame: upper respiratory infection duration, an average of 2 weeks
number and type of medication prescriptions for respiratory illness
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number and type medication prescriptions for respiratory illness. Example: 1 medication prescription, medication prescription=Tamiflu.
Time frame: upper respiratory infection duration, an average of 2 weeks
number and type of over the counter treatments used
Any subjects with confirmed or unconfirmed PCR URI will be contacted daily until symptoms subside to assess number an d type of over the counter treatments used. Example: 1 OTC treatment used, OTC treatment=ibuprofen.
Time frame: upper respiratory infection duration, an average of 2 weeks
differences in incidence of URI amongst different viruses from PCR panels
differences in incidence of URI amongst different viruses from PCR panels
Time frame: through study duration, an average of 12 weeks
treatment side effects
treatment side effects
Time frame: through study duration, an average of 12 weeks
adherence to daily use of RD-X19 device throughout study
adherence to daily use of RD-X19 device as reported to study staff at all visits (1-7)
Time frame: through study duration, an average of 12 weeks
Plan to share: Yes — Demographic and clinical data will be acquired from participants. All data will be de-identified prior to receipt by the repository, but the information needed to generate a global unique identifier for the NLM Data Archive (NDA) (clinicaltrials.gov) will be collected for each subject. Sufficient data from this project will be preserved to enable sharing via NDA data of sufficient quality to validate and replicate research findings described in the Aims. NLM requires data measured from human subjects to be shared using the NDA. Demographic data, clinical data, data collection tools and study protocols will be made available in the NDA.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: All data will be deposited to clinicaltrials following the usual NDA data submission dates.
Access criteria: Data will be findable for the research community through the NDA Collection that will be established when this application is funded. For all publications, an NDA study will be created. Each of those studies is assigned a digital object identifier (DOI). This data DOI will be referenced in the publication to allow the research community easy access to the exact data used in the publication. The research community will have access to data when the study ends. As required by NDA, studies will also be created that contain the data used for every publication. Those studies will be shared when the pre-print is available. NDA studies have digital object identifiers (DOI) to aid in findability. We will include that DOI in relevant publications. NDA will make decisions about how long to preserve the data, but that data archive has not deleted any deposited data up to now.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2028, 20 months after the start.
Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 20 months is above that.
Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
David Moss